Abstract
In search of reducing vaccine production costs', a recombinant M13 phage version of the anti-cysticercosis tripeptide vaccine (S3Pvac) was developed. The efficacy of S3Pvac-Phage vs. placebo was evaluated in a randomized trial that included 1,047 rural pigs in 16 villages of Central Mexico. Three to five months after vaccination 530 pigs were examined by tongue inspection. At 5-27 months of age, 331 pigs (197 vaccinated/134 controls) were inspected at necropsy. Vaccination reduced 70% the frequency of tongue cysticercosis and, based on necropsy, 54% of muscle-cysticercosis and by 87% the number of cysticerci.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aging / immunology
-
Animals
-
Antigens, Helminth / biosynthesis
-
Antigens, Helminth / immunology*
-
Bacteriophage M13 / immunology*
-
Bacteriophage M13 / metabolism
-
Cysticercosis / immunology*
-
Cysticercosis / prevention & control
-
Cysticercosis / veterinary*
-
Mexico
-
Rural Population
-
Swine
-
Swine Diseases / immunology*
-
Swine Diseases / parasitology
-
Swine Diseases / prevention & control*
-
Taenia solium / immunology*
-
Vaccines / immunology*
-
Vaccines / therapeutic use*
-
Vaccines, Inactivated / immunology
-
Weight Gain / drug effects
Substances
-
Antigens, Helminth
-
Vaccines
-
Vaccines, Inactivated